TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06439420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I is a non-pharmacological approach to treating sleep disturbance consisting of educational, behavioral, and cognitive intervention components with evidence-based strategies including sleep efficiency, stimulus control, and sleep hygiene modification. CBT-I includes at least 6 group sessions, each approximately 90 minutes in length, delivered over 6 weeks via telehealth.
Study: NCT05231083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital Nerves Stimulation
Description: Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital Nerves Stimulation
Description: Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
Study: NCT05723588

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: nicotine replacement therapy
Description: All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum.
Study: NCT05318157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIT drops
Description: Once a day
Study: NCT05012670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Paxalisib Capsule
Description: Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
Study: NCT05055492

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Take home saliva kits
Description: Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
Study: NCT04796870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Brain and Balance Training Program
Description: The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
Study: NCT04685161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical extrusion
Description: Invasive treatment option for fractured tooth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fibre post
Description: Easy approach for treatment
Study: NCT05711446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double Voiding
Description: Participant will be instructed to void twice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Voiding
Description: Participant will void as usual
Study: NCT05767879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated.
Study: NCT05145218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel is a novel anti-microtubule agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
Study: NCT05220267

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib plus Sintilimab
Description: Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
Study: NCT05439213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 0,33 Mg/mL Solution for Injection
Description: adrenaline dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 1 Mg/mL Solution for Injection
Description: adrenaline dosage
Study: NCT05318157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops
Description: The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
Study: NCT06085456

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematologic features
Description: Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematologic features
Description: Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
Study: NCT04161365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct visual urethrotomy
Description: Urethral stricture is treated with urethrotomy under visual control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Autologous fat graft is gathered and injected to stricture
Study: NCT04101838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: inactivated seasonal influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: inactivated seasonal influenza vaccine
Study: NCT04764916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine will be used as adductor canal block
Study: NCT04101838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax
Description: inactivated seasonal influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High-Dose
Description: inactivated seasonal influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: inactivated seasonal influenza vaccine
Study: NCT05992727

Intervention type: DIAGNOSTIC_TEST
Intervention: Galectin 3 measurement in serum and saliva by ELIZA
Description: Galectin 3 measurement in serum and saliva by ELISA in the two groups
Study: NCT04764916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: This is the facility's standard of care medication for this procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: This is the facility's standard of care medication for this procedure
Study: NCT04752644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN294B
Description: MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
Study: NCT05298267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Do Not Disturb While Driving
Description: Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
Study: NCT04752644

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TBS (Placebo) as intramuscular injections (0.5ml)
Study: NCT05258188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted Soft Tissue Mobilization
Description: Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressive Myofascial Release Technique
Description: Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
Study: NCT05437744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Description: 8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Description: 8 sockets that will be treated by immediate implant placement and sealed by PRF.
Study: NCT05373888

Intervention type: DEVICE
Intervention: Flexima®/Softima® stoma bags
Description: One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)
Study: NCT00291213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05342038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-02
Description: Stent retriever
Study: NCT05194722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wysa mobile app
Description: Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available.
Study: NCT05523271

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD EYE (Computer Aided Diagnosis ----?
Description: CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
Study: NCT04307615

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oxygen + continuous positive airway pressure (CPAP)
Description: Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen: 20 min treatment followed by 10 min rest and assessment
Study: NCT05292547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
Study: NCT05860270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Patients in the intervention group will receive oral cholecalciferol 4000U per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will receive placebo 2 capsules per day.
Study: NCT04800952

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples and filtered fluid will be collected.
Description: Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF.
Study: NCT06530433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRCard + TCPR Link App and Web
Description: Application that allows responder to perform CPR with two-way audio communication and one-way video streaming to SCDF Dispatcher

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPRCard Only
Description: Control arm with standard care of procedure that Bystander using CPRCard only
Study: NCT05251389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
Study: NCT05702346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhance Physical Activity (EPA)
Description: EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Physical Activity (EPA)
Description: EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
Study: NCT05638789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)
Description: EST alone vs EST plus EPLBD in removing common bile duct stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)
Description: EST alone vs EST plus EPLBD in removing common bile duct stone
Study: NCT05638919

Intervention type: DRUG
Intervention: Oral Antiviral
Description: Nirmatrelvir plus ritonavir or molnupiravir
Study: NCT04782206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior hypogastric plexus block
Description: superior hypogastric plexus chemical neurolysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency at S3 root plus superior hypogastric plexus block
Description: pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
Study: NCT04287543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
Study: NCT04938297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, Zanubrutinib
Description: Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, Zanubrutinib
Description: Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, Zanubrutinib
Description: Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Zanubrutinib
Description: Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
Study: NCT05666557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual erector spinae myofascial realease
Description: The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-myofascial release technique
Description: The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics.
Study: NCT05011591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming economy
Description: Detailed in arm's section
Study: NCT06424496

Intervention type: OTHER
Group type: OTHER
Intervention: Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
Description: Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
Study: NCT04829084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-post educational intervention
Description: To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
Study: NCT05468047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride injection
Description: Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
Study: NCT06376903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise - pelvic floor exercise - home advices
Description: Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise - pelvic floor exercise - home advices
Description: Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A).
Study: NCT04713761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage).
Study: NCT05853471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.